Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies with the potential to significantly improve the treatment of immune diseases and cancer. The company's lead program, soquelitinib, is a first-in-class oral therapy that selectively inhibits ITK (interleukin-2-inducible T-cell kinase) to modulate and control parallel signaling pathways in the immune system. The founding team includes inventors and scientists behind Rituxan (rituximab), Imbruvica (ibrutinib), and Zelboraf (vemurafenib). ITK inhibition represents a novel approach to immune modulation that the company believes parallels the transformative impact of those landmark therapies in oncology and autoimmune disease.